Brief: Biofrontera Enrolls First Patient To Phase IIb Clinical Study Evaluating Ameluz® / Bf-Rhodoled®
13/12/2021 14:09
Dec 13 (Reuters) - BIOFRONTERA AG B8FGn.DE :
* BIOFRONTERA ENROLLS FIRST PATIENT TO PHASE IIB CLINICAL
STUDY
EVALUATING AMELUZ® / BF-RHODOLED® FOR ACNE
* "WE BELIEVE THAT AMELUZ®-PDT HAS POTENTIAL TO EXPAND
TREATMENT
OPTIONS FOR MILLIONS OF PEOPLE SUFFERING FROM MODERATE TO SEVERE
ACNE IN US," SAYS BIOFRONTERA AG'S CEO HERMANN LÜBBERT
* A TOTAL OF SEVEN SITES ARE PARTICIPATING IN STUDY
Source text for Eikon: ID:nPexGXF86a
Further company coverage: B8FGn.DE
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 6600;))
Recent news on Biofrontera AG
See all newsBrief: Biofrontera Says Co And Units Have Entered Into An Agreement With Biofrontera Inc About How To Settle Payment Obligations By Biofrontera Inc
Brief: Biofrontera AG Says Legal Dispute On Import In USA Will Result In Revised Outlook
Brief: Biofrontera AG Resolves Capital Increase From Authorized Capital
Brief: Biofrontera AG Says Plans Capital Reduction And Considers Subsequent Capital Increase From Authorized Capital
Brief: Biofrontera AG Says FY 2022 Total Revenue Amounted To EUR 25.7 Million